{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:15:35Z","timestamp":1792278935396,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T00:00:00Z","timestamp":1411084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10620-014-3365-2","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T21:21:41Z","timestamp":1411075301000},"page":"458-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy"],"prefix":"10.1007","volume":"60","author":[{"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Modolell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Perez","family":"Aisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Castro-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cosme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Fern\u00e1ndez-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia C.","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n G.","family":"McNicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"key":"3365_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection\u2014the Maastricht IV\/florence consensus report. Gut. 2012;61:646\u2013664.","journal-title":"Gut"},{"key":"3365_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/hel.12075","volume":"18","author":"A O\u2019Connor","year":"2013","unstructured":"O\u2019Connor A, Molina-Infante J, Gisbert JP, O\u2019Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter. 2013;18:58\u201365.","journal-title":"Helicobacter"},{"key":"3365_CR3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1398-9995.1973.tb02565.x","volume":"28","author":"M Muranaka","year":"1973","unstructured":"Muranaka M, Okumura H, Takeda K, Koizumi K, Igarashi H. Population studies on drug hypersensitivities. Acta Allergol. 1973;28:50\u201361.","journal-title":"Acta Allergol"},{"key":"3365_CR4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.gastrohep.2013.01.011","volume":"36","author":"JP Gisbert","year":"2013","unstructured":"Gisbert JP, Calvet X, Bermejo F, et al. III Spanish consensus conference on Helicobacter pylori infection. Gastroenterol Hepatol. 2013;36:340\u2013374.","journal-title":"Gastroenterol Hepatol"},{"key":"3365_CR5","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02687.x","volume":"22","author":"JP Gisbert","year":"2005","unstructured":"Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther. 2005;22:1041\u20131046.","journal-title":"Aliment Pharmacol Ther"},{"key":"3365_CR6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.dld.2009.06.007","volume":"42","author":"JP Gisbert","year":"2010","unstructured":"Gisbert JP, Perez-Aisa A, Castro-Fernandez M, et al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis. 2010;42:287\u2013290.","journal-title":"Dig Liver Dis"},{"key":"3365_CR7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1083-4389.2004.00195.x","volume":"9","author":"JP Gisbert","year":"2004","unstructured":"Gisbert JP, Badia X, Roset M, Pajares JM. The TETRA study: a prospective evaluation of Helicobacter pylori \u2018test-and-treat\u2019 strategy on 736 patients in clinical practice. Helicobacter. 2004;9:28\u201338.","journal-title":"Helicobacter"},{"key":"3365_CR8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1046\/j.1365-2036.2000.00844.x","volume":"14","author":"JP Gisbert","year":"2000","unstructured":"Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14:1319\u20131328.","journal-title":"Aliment Pharmacol Ther"},{"key":"3365_CR9","unstructured":"Gisbert JP, Maria Pajares J. Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review. Med Clin (Barc). 2001;116:111\u2013116."},{"issue":"62","key":"3365_CR10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","volume":"12","author":"F Megraud","year":"2013","unstructured":"Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;12:34\u201342.","journal-title":"Gut"},{"key":"3365_CR11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.gastrohep.2013.02.006","volume":"36","author":"J Molina-Infante","year":"2013","unstructured":"Molina-Infante J, Gisbert JP. Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007\u20132012)]. Gastroenterol Hepatol. 2013;36:375\u2013381.","journal-title":"Gastroenterol Hepatol"},{"key":"3365_CR12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1440-1746.2006.04171.x","volume":"21","author":"M Matsushima","year":"2006","unstructured":"Matsushima M, Suzuki T, Kurumada T, et al. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection. J Gastroenterol Hepatol. 2006;21:232\u2013236.","journal-title":"J Gastroenterol Hepatol"},{"key":"3365_CR13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10620-005-2549-1","volume":"50","author":"M Rodriguez-Torres","year":"2005","unstructured":"Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci. 2005;50:634\u2013639.","journal-title":"Dig Dis Sci"},{"key":"3365_CR14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","volume":"26","author":"L Fischbach","year":"2007","unstructured":"Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343\u2013357.","journal-title":"Aliment Pharmacol Ther"},{"key":"3365_CR15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","volume":"377","author":"P Malfertheiner","year":"2011","unstructured":"Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905\u2013913.","journal-title":"Lancet"},{"key":"3365_CR16","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.3748\/wjg.14.5385","volume":"14","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP. \u201cRescue\u201d regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008;14:5385\u20135402.","journal-title":"World J Gastroenterol"},{"key":"3365_CR17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.2002.01276.x","volume":"16","author":"JP Gisbert","year":"2002","unstructured":"Gisbert JP, Pajares JM. Review article: Helicobacter pylori \u201crescue\u201d regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047\u20131057.","journal-title":"Aliment Pharmacol Ther"},{"key":"3365_CR18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00003495-200868040-00011","volume":"68","author":"VR Anderson","year":"2008","unstructured":"Anderson VR, Perry CM. Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs. 2008;68:535\u2013565.","journal-title":"Drugs"},{"key":"3365_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/46.2.283","volume":"46","author":"JE Sanchez","year":"2000","unstructured":"Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin\/dalfopristin and new quinolones. J Antimicrob Chemother. 2000;46:283\u2013285.","journal-title":"J Antimicrob Chemother"},{"key":"3365_CR20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1590-8658(03)00432-8","volume":"35","author":"Y Watanabe","year":"2003","unstructured":"Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis. 2003;35:711\u2013715.","journal-title":"Dig Liver Dis"},{"key":"3365_CR21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.0083-8703.2006.00375.x","volume":"11","author":"D Antos","year":"2006","unstructured":"Antos D, Schneider-Brachert W, Bastlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006;11:39\u201345.","journal-title":"Helicobacter"},{"key":"3365_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.diagmicrobio.2005.12.003","volume":"55","author":"J Yahav","year":"2006","unstructured":"Yahav J, Shmuely H, Niv Y, Bechor J, Samra Z. In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis. 2006;55:81\u201383.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3365_CR23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1542-3565(04)00458-6","volume":"2","author":"C Bilardi","year":"2004","unstructured":"Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004;2:997\u20131002.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3365_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2036.2005.02522.x","volume":"22","author":"L Gatta","year":"2005","unstructured":"Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther. 2005;22:45\u201349.","journal-title":"Aliment Pharmacol Ther"},{"key":"3365_CR25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.dld.2005.06.002","volume":"37","author":"Y Matsumoto","year":"2005","unstructured":"Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37:821\u2013825.","journal-title":"Dig Liver Dis"},{"key":"3365_CR26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","volume":"101","author":"RJ Saad","year":"2006","unstructured":"Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488\u2013496.","journal-title":"Am J Gastroenterol"},{"key":"3365_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","volume":"23","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35\u201344.","journal-title":"Aliment Pharmacol Ther"},{"key":"3365_CR28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00508-010-1404-3","volume":"122","author":"Y Li","year":"2010","unstructured":"Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413\u2013422.","journal-title":"Wien Klin Wochenschr"},{"key":"3365_CR29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14656566.2013.782286","volume":"14","author":"AC Marin","year":"2013","unstructured":"Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843\u2013861.","journal-title":"Expert Opin Pharmacother"},{"key":"3365_CR30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2169\/internalmedicine.53.1677","volume":"53","author":"T Furuta","year":"2014","unstructured":"Furuta T, Sugimoto M, Yamade M, et al. Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. Intern Med. 2014;53:571\u2013575.","journal-title":"Intern Med"},{"key":"3365_CR31","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1128\/AAC.01552-08","volume":"53","author":"K Murakami","year":"2009","unstructured":"Murakami K, Okimoto T, Kodama M, et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother. 2009;53:3097\u20133099.","journal-title":"Antimicrob Agents Chemother"},{"key":"3365_CR32","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","volume":"63","author":"KF Croom","year":"2003","unstructured":"Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769\u20132802.","journal-title":"Drugs"},{"key":"3365_CR33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1523-5378.2010.00788.x","volume":"15","author":"W Gao","year":"2010","unstructured":"Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10\u00a0years in Beijing, China. Helicobacter. 2010;15:460\u2013466.","journal-title":"Helicobacter"},{"key":"3365_CR34","first-page":"409","volume":"19","author":"De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C et al","year":"2010","unstructured":"De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409\u2013414.","journal-title":"J Gastrointestin Liver Dis"},{"key":"3365_CR35","first-page":"236","volume":"34","author":"E P\u00e9rez-Trallero","year":"2011","unstructured":"P\u00e9rez-Trallero E, Ram\u00edrez-L\u00e1zaro MJ, Villar H, et al. Resistencia de Helicobacter pylori a diversos antibi\u00f3ticos: un estudio multic\u00e9ntrico espa\u00f1ol. Gastroenterol Hepatol. 2011;34:236.","journal-title":"Gastroenterol Hepatol"},{"key":"3365_CR36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","volume":"35","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209\u2013221.","journal-title":"Aliment Pharmacol Ther"},{"key":"3365_CR37","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.12089","volume":"36","author":"CY Tay","year":"2012","unstructured":"Tay CY, Windsor HM, Thirriot F, et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther. 2012;36:1076\u20131083.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3365-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-014-3365-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3365-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:44:19Z","timestamp":1559245459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-014-3365-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["3365"],"URL":"https:\/\/doi.org\/10.1007\/s10620-014-3365-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]}}}